 Connection
Makoto Miyazaki to Pharmacovigilance
This is a "connection" page, showing publications Makoto Miyazaki has written about Pharmacovigilance.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.385 |
|
|
|
-
Miyazaki M, Sakai T, Obara T, Mano N. The impact of regulation changes in the spontaneous reporting system for vaccines on reporting trends and signal detection in Japan. Pharmacoepidemiol Drug Saf. 2021 08; 30(8):1091-1100.
Score: 0.168
-
Tsuchiya M, Obara T, Miyazaki M, Noda A, Takamura C, Mano N. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade. Int J Clin Pharm. 2020 Apr; 42(2):728-736.
Score: 0.156
-
Sakamoto Y, Bando H, Aoyagi Y, Sokuoka H, Misumi T, Oba K, Mori Y, Okui J, Miyazaki M, Sadatsuki Y, Koizumi K, Otake R, Yuri A, Tajima E, Ueno T, Nakamura T, Yoshihara H, Itoya K, Annaka R, Nakamura H, Okita N, Takahashi H, Kuroda T, Nakamura K, Yoshino T, Ohtsu A. Recommendations for generating real-world evidence with regulatory-grade relevance and reliability. Int J Clin Oncol. 2026 Oct; 31(10):2075-2086.
Score: 0.061
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|